Stock Scorecard



Stock Summary for AnaptysBio Inc (ANAB) - $16.36 as of 12/9/2023 1:37:24 AM EST

Total Score

8 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ANAB

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ANAB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ANAB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for ANAB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for ANAB

Does AnaptysBio, Inc. ( ANAB ) Have the Potential to Rally 69.36% as Wall Street Analysts Expect? 12/7/2023 2:55:00 PM
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals 11/27/2023 9:15:00 PM
Atara Biotherapeutics ( ATRA ) Slumps 57% in a Month: Here's Why 11/24/2023 5:29:00 PM
Entrada ( TRDA ) Down on FDA Maintaining Clinical Hold on DMD Drug 11/23/2023 4:47:00 PM
MorphoSys ( MOR ) Down 22% on Mixed Data From Myelofibrosis Study 11/22/2023 6:48:00 PM
Gain Therapeutics ( GANX ) Down 25% on Issue of New Common Stock 11/22/2023 4:58:00 PM
Agios ( AGIO ) Meets Clinical Proof-of-Concept in Anemia Treatment 11/21/2023 3:56:00 PM
Karuna ( KRTX ) Posts Upbeat Safety Data on Schizophrenia Drug 11/17/2023 4:32:00 PM
Merck ( MRK ) Gets FDA Nod for Keytruda Expansion in Gastric Cancer 11/17/2023 4:29:00 PM
Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. ( ANAB ) Looks Ripe for a Turnaround 11/14/2023 2:35:00 PM

Financial Details for ANAB

Company Overview

Ticker ANAB
Company Name AnaptysBio Inc
Country USA
Description AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2023
Next Earnings Date 2/28/2024

Stock Price History

Last Day Price 16.36
Last Day Price Updated 12/9/2023 1:37:24 AM EST
Last Day Volume 0
Average Daily Volume N/A
52-Week High 32.44
52-Week Low 13.36
Last Price to 52 Week Low 22.46 %

Valuation Measures

Trailing PE N/A
Industry PE 57.56
Sector PE 62.37
5-Year Average PE -12.10
Free Cash Flow Ratio 1.05
Industry Free Cash Flow Ratio 10.37
Sector Free Cash Flow Ratio 31.15
Current Ratio Most Recent Quarter 10.92
Total Cash Per Share 15.54
Book Value Per Share Most Recent Quarter 4.53
Price to Book Ratio 3.61
Industry Price to Book Ratio 4.33
Sector Price to Book Ratio 19.59
Price to Sales Ratio Twelve Trailing Months 29.06
Industry Price to Sales Ratio Twelve Trailing Months 10.29
Sector Price to Sales Ratio Twelve Trailing Months 5.61

Share Statistics

Total Shares Outstanding 26,575,200
Market Capitalization 434,770,272
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Dividend King? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth -122.72 %
Reported EPS 12 Trailing Months -5.42
Reported EPS Past Year -4.49
Reported EPS Prior Year -4.57
Net Income Twelve Trailing Months -147,821,000
Net Income Past Year -128,724,000
Net Income Prior Year -57,796,000
Quarterly Revenue Growth YOY 156.60 %
5-Year Revenue Growth 32.40 %

Balance Sheet

Total Cash Most Recent Quarter 413,047,000
Total Cash Past Year 441,241,000
Total Cash Prior Year 548,097,000
Net Cash Position Most Recent Quarter 413,047,000
Net Cash Position Past Year 441,241,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 1,375,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 262,103,000
Total Stockholder Equity Prior Year 356,428,000
Total Stockholder Equity Most Recent Quarter 120,383,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.32
MACD Signal -0.67
20-Day Bollinger Lower Band 13.90
20-Day Bollinger Middle Band 17.68
20-Day Bollinger Upper Band 21.45
Beta -0.27
RSI 56.19
50-Day SMA 20.63
200-Day SMA 23.24

System

Modified 12/10/2023 5:29:50 AM EST